about
Cytokine levels in the serum of healthy subjectsDecreased Coenzyme Q10 Levels in Multiple System Atrophy CerebellumCoenzyme Q deficiency causes impairment of the sulfide oxidation pathway.Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis.Alendronate, a double-edged sword acting in the mevalonate pathway.Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency.Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds.Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo.Temperature and drug treatments in mevalonate kinase deficiency: an ex vivo study.Clinical genetic testing of periodic fever syndromesFarnesyl and geranylgeranyl transferase inhibitors: an anti-inflammatory effect. Comment to "Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells" Haematologica. 2The Role of Sulfide Oxidation Impairment in the Pathogenesis of Primary CoQ Deficiency.Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion.Mevalonate kinase deficiency and IBD: shared genetic background.Lovastatin induces apoptosis through the mitochondrial pathway in an undifferentiated SH-SY5Y neuroblastoma cell line.Mouse model of mevalonate kinase deficiency: comparison of cytokine and chemokine profile with that of human patients.Repositioning Of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice.Systemic and neuronal inflammatory markers in a mouse model of mevalonate kinase deficiency: a strain-comparative study.Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System AtrophySerum amyloid A and cholesterol: a pivotal role on inflammationCombined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in GlioblastomaMetabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in GlioblastomaMET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in GlioblastomaCoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathwayMitochondrial dysfunction in fibroblasts of Multiple System AtrophyActivation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibitionA serological assay to detect SARS-CoV-2 seroconversion in humansIntroductions and early spread of SARS-CoV-2 in the New York City area
P50
Q36711758-A822CA34-0985-4E4F-B0DF-10DB3C835F9DQ37019733-ECDA9B26-707D-4ECA-9271-7F4972C8A8E9Q37555498-DBC2C6AC-35D4-46A7-9F70-B248F36AA089Q38167274-109E6614-6A55-4338-B6AE-1D718D4CF340Q38861481-5B1E548E-131F-49B9-B6CE-45AC0EE63E57Q38871606-537CD8EB-D0AF-442B-9A10-E4309187ED02Q39001725-AA336104-7F14-4344-9D69-BFC5963D8225Q39107997-C523E9FC-A6D5-43EE-AC34-9184A21C1F3DQ39343545-ABDEB7BC-6AE9-4FF2-89C7-787663E7DD1FQ39452889-B70E56AC-B60B-4E96-BA42-93EF7CD3D5D9Q40892197-0AE74E6A-CA32-471E-A05D-65DE2AFD68F3Q41109934-25C95A79-DE33-44CA-A0D7-3EF36442420FQ41990117-4E20C44D-A51B-4629-BF13-ACED020A423CQ42483575-B37DDEFF-CCA5-4BCF-9E21-800FC8A58F7EQ42751140-C03446FF-8B38-4D74-9C25-2BF8256E94F2Q43180081-95DC97FE-FBD2-4865-BDE4-DCBA3CC653F6Q45892405-6097E358-6BEF-4DE0-99CF-4F17F7872C7AQ47812443-42D3AE26-5306-4BE7-B857-4D7F55738C1CQ54393387-9026DF24-1191-4702-938E-A1142D5A0973Q55263786-22A6CDB3-9534-4262-A0D7-03E0552B569CQ57818105-16C0FCEE-3F0E-45B7-925A-2B4DB9F584F6Q58251766-5769391A-57CF-4F52-B6A9-41EF10307AB8Q88683268-FFD5B8E2-945E-42F2-9BB7-25DA6214F4E7Q90424848-6FC15B6F-24D5-4372-9CFA-F65F73D6F920Q91150722-ED6E419C-82F5-4683-8BA7-8A284C1916F5Q91716765-0839367B-E976-4180-99ED-DD163D6FC242Q91734455-65F7FDDD-E311-40A7-AC24-8D313347B9D3Q93005150-E774B3C1-DED9-4DE2-84BA-61CEEE2C4B52Q94600837-9BF5131B-99BF-41B5-B864-17C0B04683C6Q96022059-192855D0-50BA-4591-A6D9-E40544568006
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1830-3961
@en
name
Giulio Kleiner
@ast
Giulio Kleiner
@en
Giulio Kleiner
@es
Giulio Kleiner
@nl
type
label
Giulio Kleiner
@ast
Giulio Kleiner
@en
Giulio Kleiner
@es
Giulio Kleiner
@nl
prefLabel
Giulio Kleiner
@ast
Giulio Kleiner
@en
Giulio Kleiner
@es
Giulio Kleiner
@nl
P106
P1153
52164051200
P21
P31
P496
0000-0002-1830-3961